Redbiotec today announced that it has closed a new collaboration agreement with an undisclosed company in the field of antibody generation. The goal of this collaboration is the development of new therapeutic antibodies using Redbiotec’s VLPs as targets. Under the agreement, the parties will share profit generated by the therapeutic antibodies.